Solid Tumor Therapeutics (Project-007)

该部分的标题为实体肿瘤治疗计划摘要 实体肿瘤治疗计划(STTP)专注于将基因组发现转化为 实体肿瘤的治疗方案。重点关注的基本领域是基因组技术和发现， 适用于特定疾病的发育疗法(DT)和DNA代谢与修复(DMR) 神经、胸科、胃肠、泌尿生殖和妇科肿瘤学研究。该计划是 通过领导委员会、研究会议和研讨会、务虚会和其他教育活动进行协调 活动。初级调查人员的培训是通过导师计划和NCI资助的T32、K12实施的 以及临床和转化奖(CTSA)教育项目。我们已经确定了机构领域 力量，并制定了以下目标和目的。 实体肿瘤治疗计划的科学目标是： 1.确定癌症DNA修复中可用于治疗的缺陷。 2.将基因组发现转化为实体肿瘤的创新治疗方案。 目的1.开发和应用最先进的组学技术进行实体瘤临床试验。 目的2.利用基因组学和成像技术进一步扩大我们充满活力的发展治疗集团。 目的3.将组学用于神经、胸科、胃肠、泌尿生殖系统、 和妇科肿瘤学。 目的4.明确DNA修复的分子机制，以用于新的临床试验。 研究策略是了解遗传不稳定、DNA修复缺陷和抑制剂对 实体肿瘤的启动、维持和化疗耐药。 该小组共有58名成员，分别来自14个部门和2所学校。STTP得到了3620万美元的支持，其中 NCI提供的资金为520万美元，其他同行评审的资金为148美元。2009-2014年间，STTP成员 发表了1 030篇论文，其中32%为方案间论文，12%为方案内论文 程序性协作。从2009-2014年，我们参与了798项临床试验，其中85%是 干预性。这些试验招募了11,772名患者，其中4,846人参加了介入试验。

THIS COMPONENT IS ENTITLED SOLID TUMOR THERAPEUTICS PROGRAM ABSTRACT The Solid Tumor Therapeutics Program (STTP) is focused on translating genomic discoveries in novel therapeutic protocols for solid tumors. Fundamental areas of focus are Genomics Technologies & Discovery, Developmental Therapeutics (DT) and DNA Metabolism & Repair (DMR), which apply to disease-specific studies in Neuro, Thoracic, Gastrointestinal, Genitourinary and Gynecologic Oncology. The program is coordinated through a leadership committee, research meetings and seminars, retreats and other educational activities. Training for junior investigators is implemented through a mentorship plan, and NCI-funded T32, K12 and Clinical and Translational Awards (CTSA) educational programs. We have identified areas of institutional strength and developed the following goals and aims. The scientific goals of the Solid Tumor Therapeutic Program are: 1. To define defects in DNA repair in cancer that can be therapeutically exploited. 2. To translate genomic discoveries into innovative therapeutic protocols in solid tumors. Aim 1. To develop and apply state-of-the-art ‘omics technology for solid tumor clinical trials. Aim 2. To utilize genomics and imaging to further expand our vibrant Developmental Therapeutics Group. Aim 3. To utilize ‘omics for clinical trials in solid tumors in Neuro, Thoracic, Gastrointestinal, Genitourinary, and Gynecologic Oncology. Aim 4. To define molecular mechanisms of DNA repair for use in novel clinical trials. The research strategy is to understand genetic instability, DNA repair defects and effects of inhibitors on solid tumor initiation, maintenance and chemoresistance. The STTP has 58 members from 14 departments and 2 schools. STTP is supported by $36.2 million, with $5.2 million in NCI funding and $14.8 in other peer reviewed funding. From 2009-2014, members of the STTP published 1,030 papers, of which 32% represented inter-programmatic and 12% resulted from intra- programmatic collaborations. From 2009-2014, we participated in 798 clinical trials, 85% of which were interventional. These trials enrolled 11,772 patients, of which 4,846 were enrolled onto interventional trials.